AZI2

Across TCGA pan-cancer cohorts, AZI2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated AZI2 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher AZI2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AZI2 expression acts as an unfavorable survival marker.

BRCA, LUSC, and BLCA are the cancer types where AZI2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.110	0.578	.006	24	view →
LUSC	OS	Median	III,IV	0.112	0.664	.003	12	view →
BLCA	DFS	Median	All	0.015	0.594	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

AZI2–BRCA (OS)

Open the BRCA breakdown →